Please fax all pages of completed form to your team at 877.251.5897.

To reach your team, call toll-free 877.445.3951.

You can now monitor shipments and chat online if you have questions. Go to <a href="MyAccredoPatients.com">MyAccredoPatients.com</a> to log in or get started.

**Prescription & Enrollment Form** 

## Fasenra® (benralizumab)



## Four simple steps to submit your referral.

4		and municipal spaces of front and back of all madical	
<b>■</b> Patient Information		ease provide copies of front and back of all medical d prescription insurance cards.	
New patient			
Patient's first name	Last name	Middle initial	
Preferred patient first name	Preferred patient last name		
Sex at birth: Male Female Gender identity	Pronouns	Pronouns Last 4 digits of SSN	
Date of birthStreet address		Apt #	
City	_ State	Zip	
Home phone Cell phone		Email address	
Parent/guardian (if applicable)			
Home phone Cell phone		Email address	
Alternate caregiver/contact			
Home phone Cell phone		_ Email address	
OK to leave message with alternate caregiver/contact			
Patient's primary language: English Other If other, p	lease specify		
<b>2</b> Prescriber Information	All fields n	nust be completed to expedite prescription fulfillment.	
Date Time	Date medic	ation needed	
Office/clinic/institution name			
Prescriber info: Prescriber's first name		Last name	
Prescriber's title			
Office phone Fax	NPI #	License #	
Office contact and title		Office contact email	
Office street address		Suite #	
City	State	Zip	
Infusion location: Patient's home Prescriber's office I		site, complete information below dotted line:	
Influsion info. Influsion cita name			
Infusion info: Infusion site name			
Site street address City		Suite # Zip	
Infusion site contact Phone _		·r	
3 Clinical Information		Email	
ICD-10 code (REQUIRED):			
NKDA Known drug allergies			
Prior anaphylactic reaction: No Yes (Reason/date			
Concurrent meds Short-acting beta agonist Long	g-acting heta agonist	Antihistamines Decongestants Immunotherapy	
Inhaled corticosteroid Leukotriene modifiers Oral str			
		- Ouldi	
Lab results: History of positive skin OR RAST test to a pe	_	treatment serim equipophile	
Pre-treatment serum IgE levelIU per mL Test d			
sputum eosinophils Date			
	NI Primary care I ed therapy	Pediatrician Other	

Prescriber's first name	Last name		Phone
4 Prescribing Info	ormation		
Medication	Strength / Formulation and Directions		Quantity/Refills
Fasenra® (benralizumab) 30mg/mL solution in a single- dose prefilled syringe (PFS) Fasenra® (benralizumab) 30mg/mL auto-injector pen Fasenra® (benralizumab) 10mg/0.5mL solution in a single-dose PFS Other	Starter Dose: Inject 30mg under the first 3 doses, followed by once every Maintenance Dose: Inject 30mg und Starter Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses, followed by once every Maintenance Dose: Inject 10mg under the first 3 doses followed by once every Maintenance Dose: Inject 10mg under the first 3 doses followed by once every Maintenance Dose: Inject 10mg under the first 3 doses followed by once every Maintenance Dose: Inject 10mg under the first 3 doses followed by once every Maintenance Dose: Inject 10mg under the first 3 doses followed by once every Maintenance Dose: Inject 10mg under the first 3 doses followed by once every Maintenance Dose: Inject 10mg under the first 3 doses followed by once every Maintenance Dose followed by Once every Maintenanc	8 weeks thereafter. er the skin every 8 weeks. skin every 4 weeks for the 8 weeks thereafter.	1-month supply 3-month supply Other:  Refills  Patient Weightkg
Ι,	me Authorization for Administration at MDC	me) as treating healthcare (Patient's DOB)	provider for am requesting Fasenra® (benralizumab)
Prescriber's signature (sign below)	(Physician attests this is his/her legal s	ignature. NO STAMPS)	or infusion clinic.
The prescriber is to comply with his/hea	r state-specific prescription requirements such	as e-prescribing state-specific	prescription form fax language etc

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_ Date of birth \_\_\_\_\_

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc Non-compliance with state-specific requirements could result in outreach to the prescriber.

